Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Blackrock Inc

Danaher

The Zacks Research Daily presents the best research output of our analyst team.

Top Research Reports for Roche, Danaher & BlackRock

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Novartis

Invitae

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

Roche Holding AG (RHHBY) CEO Severin Schwan on Q1 2019 Results - Earnings Call Transcript

Roche had achieved positive preliminary results in its phase 1b study using a Tecentriq triple-combination therapy in patients with advanced TNBC.

Roche's Latest Triple-Combination Data In Breast Cancer Lays Groundwork To Target Other Cancer Indications

Roche said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

Roche says its $4.3 billion offer for Spark is still on track for June completion

ADMA Biologics

Advaxis

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Johnson & Johnson

Merck

The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.

3 Big Pharma Stocks to Add to Your Portfolio This April

Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.

Roche's 'Steep' Spark Buyout Could Put These Gene Therapy Names In Play

Aurora Cannabis

Heineken NV

Coca-Cola

Mondelez

Partnering with any of these four well-known companies would make a lot of sense for Canada's top-producing marijuana stock.

Aurora Cannabis: 4 Logical Brand-Name Partners

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Roche Holding’s  Ocrevus has been on a stellar run with sales exceeding $2.4 billion in 2018, reflecting a growth of 2.8x over the prior year

How Much Can Roche's Share Price Grow If Ocrevus Doubles Its Share In Multiple Sclerosis Market?

Roche has the pipeline and the balance sheet to handle what may come

News for Roche Holding AG Stock (RHHBY)